Who Paid My Doc
BI 767551 EX 14870 Ph III in SARS Cov 2 Preventi
Research payments
$497,553
Through program year 2022, $497,553 in research payments was reported against BI 767551 EX 14870 Ph III in SARS Cov 2 Preventi, across 96 payments, paid by Boehringer Ingelheim Pharmaceuticals, Inc..
- Paid by
- Boehringer Ingelheim Pharmaceuticals, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $41,912 | 5 |
| 2021 | Research | $455,641 | 91 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Edward Cordasco Columbus, OH Named on 3 payments
- Jose Cardona Hialeah, FL Named on 3 payments
- Carl Dukes San Antonio, TX Named on 2 payments
- Avinash Shah Charlotte, NC Named on 2 payments
- Wilner Jeudy Sugar Land, TX Named on 2 payments
- Murtaza Mussaji Pearland, TX Named on 2 payments
- Gilberto Perez Hialeah, FL Named on 2 payments
- Rajasekaran Annamalai Tomball, TX Named on 2 payments
- Pablo Perez Dalton, GA Named on 2 payments
- Robert Falcone Raritan, NJ Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.